Implantable cardioverter defibrillator: What a hospital practitioner needs to know

Albouaini, Khaled; Mudawi, Telal; Pyatt, Jason; Wright, David J.

doi:10.1016/j.ejim.2009.06.006

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sudden cardiac death (SCD), defined as cardiac death occurring within 1 h of symptom onset, is a major cause of mortality in Australia . Over 80% of cases are due to ventricular fibrillation or ventricular tachycardia . Survival following an out‐of‐hospital sudden cardiac event remains poor and is estimated to be less than 5% .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Trends in the use of implantable cardioverter defibrillators in Australia: a 10‐year nationwide study from 2000–2009

Burch

Wong

Sullivan

et al. 2013

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Over 80% of cases are due to ventricular fibrillation or ventricular tachycardia . Survival following an out‐of‐hospital sudden cardiac event remains poor and is estimated to be less than 5% . Therefore, SCD represents a considerable public health issue.…”

Section: Introductionmentioning

confidence: 99%

Trends in the use of implantable cardioverter defibrillators in Australia: a 10‐year nationwide study from 2000–2009

Burch

Wong

Sullivan

et al. 2013

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…1 Complications relate to device insertion, mechanical malfunction, or infection. One large prospective study reported an incidence of 0.68 infections per 100 patients in the 12 months subsequent to implantable cardioverterdefibrillator (ICD) insertion.…”

Section: Introductionmentioning

confidence: 99%

Fortuitous Vasculitis

et al. 2012

View full text Add to dashboard Cite

A 43-year-old man with a cardiac device for dilated cardiomyopathy presented with fever, night sweats, and weight loss. Investigations revealed pancytopenia, acute renal failure, abnormal lung function, and raised inflammatory markers. A renal biopsy demonstrated pauci-immune necrotizing crescentic glomerulonephritis. He was diagnosed with pulmonary-renal antineutrophil cytoplasmic antibody-negative systemic small vessel vasculitis. He commenced immunosuppression with prednisolone and cyclophosphamide with recovery from pancytopenia and improvement in renal function 3 months later. Subsequently, a bone marrow culture grew Mycobacterium fortuitum. Isolation on repeat peripheral mycobacterial blood cultures prompted treatment with ciprofloxacin and clarithromycin. Four months later, he presented with neutropenic sepsis, influenza A/H1N1, and Aspergillus flavus pneumonia. Despite treatment he deteriorated. A transthoracic echocardiogram revealed a vegetation on the right ventricular pacing wire. The device was removed. The vegetation revealed acid and alcohol fast bacilli on Ziehl-Neelsen staining and grew M. fortuitum on culture, sensitive to ciprofloxacin and clarithromycin. Despite device removal and antimicrobial therapy, the patient succumbed to treatment-related complications. The association between glomerulonephritis and endocarditis is well known; however, this is the first case to our knowledge describing pauci-immune necrotizing crescentic glomerulonephritis in the context of M. fortuitum endocarditis. Clinicians should maintain a high index of suspicion for endocarditis in patients with a cardiac device who present with fever and pauci-immune necrotizing crescentic glomerulonephritis. Patients should be investigated with mycobacterial blood cultures, at least three sets of standard blood cultures and transthoracic and transesophageal echocardiography. Clinicians should beware the perils of immunosuppression in the face of an occult sepsis.

show abstract

Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients—a systematic review and meta-analysis

et al. 2018

View full text Add to dashboard Cite

Implantable cardioverter-defibrillator (ICD) has shown to reduce sudden cardiac death and overall mortality in patients with dilated cardiomyopathy. The recently published DANISH trial has shown conflicting outcomes on the long-term survival in patients with prophylactic implantation of ICD in Non-Ischemic Cardiomyopathy (NICM). Two independent reviewers searched MEDLINE, PUBMED, Ovid, CINAHL, clinicaltrials.gov , and Cochrane Registry for randomized control trials (RCT's) comparing ICD to medical treatment (MT). Six RCT's enrolling 3389 patients (ICD = 1554 and MT = 1835) were included for final analysis. The primary outcomes were mortality comparing ICD to MT, 231 vs 337 (OR = 0.74, CI = 0.62-0.90, p = 0.002, and I = 0%) favoring ICD. On comparing to amiodarone only, there were 47 deaths in the ICD arm vs 71 deaths in amiodarone arm, (OR = 0.66, CI = 0.44-0.98, p = 0.04, I 0%), to placebo and usual care only (excluding amiodarone); there were 225 deaths in ICD patients compared to 266 in the placebo and usual care arm, (OR = 0.73, CI = 0.59-0.92, p = 0.007, I = 15%). The results of our analysis from these six RCTs clearly support the ongoing benefit of prophylactic ICD implantation and support current recommendations for ICD implantation in NICM patients. More RCT's at a larger scale are needed to further elucidate benefits of both ICD and CRT-D in this post PARADIGM era where MT is at a pinnacle in reducing morbidity and mortality in heart failure patients.

show abstract

Implantable cardioverter defibrillator: What a hospital practitioner needs to know

Cited by 4 publications

References 26 publications

Trends in the use of implantable cardioverter defibrillators in Australia: a 10‐year nationwide study from 2000–2009

Trends in the use of implantable cardioverter defibrillators in Australia: a 10‐year nationwide study from 2000–2009

Fortuitous Vasculitis

Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients—a systematic review and meta-analysis

Contact Info

Product

Resources

About